ClinicalTrials.gg
RecruitingNCT06892717Updated Mar 25, 2025

Caregiver Burden in Parkinson's Disease

An observational study in Parkinson Disease, sponsored by Beylikduzu State Hospital. Recruiting at 1 site in Turkey. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Beylikduzu State Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
43
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Planned enrollment
52nd of 73
43 · median 61
Started
2025
with 32 others
Observational
73 of 172
23 open now
Primary completion
2025-04
later than 12 of 55 live
Registered
104th of 172
by date

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 52nd largest by planned enrollment of the 73 observational ones that give a count, is one of 33 that started in 2025, is one of 73 observational ones, reaches primary completion later than 12 of the 55 other live ones, and was the 104th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

Primary caregivers of patients diagnosed with idiopathic Parkinson's disease will be included in the study. A total of 43 participants will be recruited. At the beginning of the study, demographic data and clinical characteristics of the patients, including disease stage, history of falls, presence of fractures, presence and severity of pain, comorbidities, and medication use, will be recorded.

Subsequently, caregivers' age, gender, occupation, relationship to the patient, caregiving duration, and their own comorbidities will be assessed. Sleep problems will be evaluated using the Insomnia Severity Index (ISI), while symptoms related to depression and anxiety will be assessed with the Hospital Anxiety and Depression Scale (HADS). Caregiver burden will be examined using the Zarit Caregiver Burden Scale.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will consist of caregivers of patients diagnosed with Parkinson's disease, aged between 40-80 years, who meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40-80 years
  • Diagnosed with Parkinson's disease, Hoehn and Yahr stage 2-5
  • Requires assistance in daily activities
  • Informal caregiver providing care (unpaid, typically a family member such as a spouse or child)
  • Caregiver has sufficient proficiency in Turkish to understand and respond to the study questions

Exclusion criteria

Exclusion Criteria:

  • Presence of any additional neurodegenerative disease other than Parkinson's disease
  • Diagnosis of (COPD)
  • Advanced heart failure classified as (NYHA) Class IV (symptoms at rest)
  • Active cancer disease
  • History of stroke causing limitations in daily life
  • Immobility due to reasons other than Parkinson's disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
43 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Zarit Caregiver Burden Scale

    A scale used to assess the physical, emotional, and social burden of caregiving, with higher scores indicating greater caregiver burden. Score range: 0-88.

    Time frame: Baseline

Secondary outcomes

  1. Insomnia Severity Index (ISI)

    A scale used to evaluate the severity of sleep problems in caregivers, with higher scores reflecting more severe insomnia. Score range: 0-28.

    Time frame: Baseline

  2. Hospital Anxiety and Depression Scale (HADS)- Anxiety score

    A tool used to assess symptoms of anxiety in caregivers. Higher scores indicate more severe anxiety. Score range: 0-21.

    Time frame: Baseline

  3. Hoehn and Yahr Scale

    A classification system used to determine the disease stage of Parkinson's disease, with higher stages indicating more severe disease progression. Score range: 1-5.

    Time frame: Baseline

  4. Visual Analog Scale (VAS)

    A linear scale used to assess pain severity, where higher scores indicate more severe pain. Score range: 0-10.

    Time frame: Baseline

  5. Hospital Anxiety and Depression Scale (HADS)- Depression score

    A tool used to assess symptoms of depression in caregivers. Higher scores indicate more severe depressive symptoms. Score range: 0-21.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Beylikdüzü State Hospital
    Istanbul, Beylikdüzü 34147, Turkey
    Recruiting
    • Büşra Şirin · Contactbsrn080@gmail.com · 02124443322
    • Büşra Şirin Ahısha, MD · Principal investigator
    • Nurdan Paker, Prof · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Apr 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2025
First posted
Mar 25, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Apr 10, 2025
CompletionEst.
Apr 10, 2025
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06892717
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Mar 25, 2025
Start date
Feb 10, 2025
Primary completion
Apr 10, 2025 (estimated)
Completion
Apr 10, 2025 (estimated)
Last update
Mar 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion